Sutro Biopharma (STRO) IPO Opens Modestly Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St set to open higher as pause in US-Iran hostilities lifts sentiment
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices near one-week low after US, Iran pause fighting over weekend
- Jefferies turns bullish on Ford, GM ahead of earnings, citing stronger margins
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
- Strategy sells MSTR shares, doesn't buy bitcoin
Sutro Biopharma Announces $85.0 Million Initial Public Offering
September 26, 2018 6:58 PM EDTSOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 /PRNewswire/ -- Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share. All of the shares are being offered by Sutro. The shares are expected to begin trading on The Nasdaq Global Market on September 27, 2018 under the symbol... More
